Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related
Audit Report or Completed Interim Review
On October 28, 2022, the Board of Directors of Instadose Pharma Corp was
notified by our independent Auditor BF Borgers CPA PC (the "Auditor") that
Instadose is required to disclose that the February 28, 2022, financial
statements were not reviewed by the Auditor.
On November 2, 2022, the Company's Board of Directors met and then acting under
authority delegated to it, approved the disclosure described below in this Form
8-K.
Instadose is advising that the financial statements as at February 28, 2022 and
the associated 10-Q were not reviewed by the Auditor. Management of Instadose
provided disclosure that the financial statements and 10-Q were unaudited,
however, further disclosure is now being provided that the February 28, 2022,
financial statements and 10-Q were also not reviewed by the Auditor.
Instadose has requested that the Auditor furnish it with a letter addressed to
the Securities and Exchange Commission stating whether or not it agrees with the
above statement. A copy of the letter from the Auditor Firm is attached hereto
as Exhibit 16.1 to this Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
16.1 Letter from BF Borgers CPA PC
104 Cover Page Interactive Data File (embedded within the Inline XBRL
Document)
2
© Edgar Online, source Glimpses